Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914197 | 1.00 | KDR (0.38) | KDRMAPK14AURKAAAK1NTSR1 | |
| SCHEMBL5914251 | 0.84 | BRD4 (0.38) | KDRMAPK14AAK1GLS | |
| SCHEMBL5914249 | 0.84 | BRD4 (0.38) | KDRMAPK14AAK1GLS | |
| SCHEMBL5914098 | 0.82 | MAPK14 (0.39) | KDRMAPK14GLS | |
| SCHEMBL5914093 | 0.82 | MAPK14 (0.39) | KDRMAPK14GLS | |
| SCHEMBL5914387 | 0.80 | BRD4 (0.35) | KDRMAPK14GLS | |
| SCHEMBL5913875 | 0.80 | KDR (0.38) | KDRMAPK14 | |
| SCHEMBL5913890 | 0.80 | KDR (0.38) | KDRMAPK14 | |
| SCHEMBL5914005 | 0.79 | NAMPT (0.37) | MAPK14GLS | |
| SCHEMBL5914003 | 0.79 | NAMPT (0.37) | MAPK14GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | KDR 210/4885MAPK14 2620/4885AURKA 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.